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Review of the literature revealed that our patient presented with typical features of 
DIPNECH (Table 1). The majority of patients are symptomatic and are misdiagnosed 
for years.  
DiscussionIntroduction
A 70-year-old Caucasian female life-long non-smoker 
with a chronic cough of 25 year duration had been 
unsuccessfully treated for presumed allergic rhinitis, 
postnasal drip, and cough variant asthma. Bronchoscopy 
was unrevealing while a HRCT scan of the chest 
discovered two pulmonary nodules with moderate air 
trapping on expiratory imaging (Figure 1). 
The patient underwent wedge resection with pathology 
revealing carcinoids with tumorlets and PNEC hyperplasia 
(Figure 2). These tumors were hormonally inactive and 
a full workup disclosed no metastases. Her current 
treatment consists of cough suppression with an opiate.
Case
•  Pulmonary neuroendocrine cells (PNECs) span 
the entire respiratory tract, synthesizing amines, 
peptides, and cytokines (serotonin, gastrin, 
chromogranin A, and bombesin). They are known to 
undergo reactive hyperplasia in response to chronic 
injury. 
•  The World Health Organization (WHO) recognized 
diffuse idiopathic pulmonary neuroendocrine cell 
hyperplasia (DIPNECH) as a primary, pre-invasive 
form of PNEC proliferation with a spectrum ranging 
from tumorlet to carcinoid tumor formation within 
the terminal and respiratory bronchioles (1999).  
•  DIPNECH can lead to varying degrees of obstructive 
ventilatory defects secondary to fibrosis and 
proliferation of PNECs beyond the basement 
membrane. 
•  High resolution CT (HRCT) screening has led to the 
increasing recognition and understanding of the 
disease, accounting for 130 cases described in 
current literature.
Table 1. Features of DIPNECH (N=109)
 
Sex Female predominance of 92%
Age 34 - 78 years (mean 57; median 62)
Ethnicity Caucasian predominance suggested
Tobacco History 33% active/former smokers
Symptomatic 55% - 89%
Symptom Type Cough (71%), dyspnea (63%), wheezing (25%)
Duration 6 months to > 2 decades
PFT Obstructive (63-86%), restrictive (13%), mixed (17%), nurmal (17%)
HRCT Findings 96% air trapping, 62% one or more pulmonary nodules, 29% ground glass, 21% bronchiectasis
Biopsy Results 88% tumorlets, 40% carcinoid tumors, 44% constrictive bronchiolitis
Prognosis (2-5yr) 41-45% stable course, 26-32% decline on PFT, 35% improved with treatment (inhaled steroids 67%, oral steroids 46%, octreotide 17%)
•  Transbronchial biopsy and lavage have shown a low yield while PFT testing 
reveals an obstructive pattern in most symptomatic patients. 
•  HRCT scans should be obtained with the addition of expiratory imaging to aid 
in recognition of the mosaic pattern of air trapping suggestive of constrictive 
obliterative bronchiolitis.  
•  The current gold standard of diagnosis remains a surgical lung biopsy with 
histopathologic confirmation. 
•  Typical disease course is indolent and non-progressive with a small 
percentage of cases experiencing clinical deterioration. The majority of 
patients have a favorable long term survival with observation alone. 
•  While there is no known definitive treatment for DIPNECH, limited data 
reports improvement with systemic/inhaled steroids. Somatostatin analogs 
such as Octreotide have inconsistently shown stabilization of disease 
progression. 
•  The use of cytotoxic agents is not recommended and may be detrimental. 
Elevated serum biomarkers and ipsilateral lymph nodal metastasis have 
been reported but did not predict a poorer outcome. 
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Figure 1a: HRCT - Right upper lobe pulmonary nodules.
Fig. 1a 
Figure 1b: HRCT – Expiratory image demonstrating air 
trapping (Post right upper wedge resection).
Fig. 1b 
